Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with resectable mucosal melanoma, confirmed through laboratory analysis of tissue samples
• People who are able to provide 5 stored tissue samples taken before treatment, or who are willing to have a needle biopsy to collect tissue for testing
• People who are in good general health, able to carry out normal daily activities with little or no limitation (confirm with trial site)
• People who have never been treated with certain immune-based cancer therapies, including anti-CTLA-4, anti-PD-1, or anti-PD-L1 medications
• People who have never been treated with a type of chemotherapy called taxane-based drugs
• People who have at least one measurable tumour lesion, as assessed using standard imaging guidelines
• People who have not used immune-suppressing medications in the 6 months before joining the trial
• People whose blood test results meet specific requirements for blood cell counts, kidney function, and liver function (confirm with trial site)
• Women who could become pregnant must have a negative pregnancy test and agree to use an appropriate form of contraception during the trial

Who may not be able to join:

• People whose cancer has spread to distant parts of the body
• People with an active autoimmune disease, although some exceptions may apply for certain conditions such as vitiligo, type 1 diabetes, or an underactive thyroid managed only with hormone replacement (confirm with trial site)
• People who need high-dose steroid tablets or other immune-suppressing medications within 14 days of joining — though inhaled or topical steroids may be acceptable in some cases (confirm with trial site)
• People currently being treated for another type of cancer, unless that cancer has been in complete remission for 2 or more years and no further cancer treatment is needed during the study
• People who, in the investigator's assessment, are unable to complete the study or understand the information provided, for medical, psychological, or physical reasons
• People who have previously received any immune checkpoint therapy targeting PD-1, PD-L1, PD-L2, CTLA-4, or similar pathways
• People who have previously received taxane-based chemotherapy
• People who have tested positive for HIV or have been diagnosed with AIDS
• People with a known allergy or sensitivity to the study medications
• Women who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.